Retrotope, Inc.
LOS ALTOS, CA · CIK 0001607677 · Biotech · Private
Small-molecule therapeutics that down-regulate lipid peroxidation (LPO) to protect cells from degeneration
retrotope.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $32M
- 7 Form D · Aug 2020
- 73 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 17 granted · 23 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201320142015201620172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $5,809,000 | |
| Private capital raised | Form D · SEC | $2,727,869 | |
| Private capital raised | Form D · SEC | $2,350,000 | |
| Private capital raised· 1 of 2 same day | Form D · SEC | $4,330,506 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $3,000,000 | |
| Private capital raised | Form D · SEC | $4,067,933 | |
| Private capital raised | Form D · SEC | $10,100,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2297 | SYNDEVRX INC | — | $38M |
| 2298 | Zya, Inc. | — | $37M |
| 2299 | Cyclacel Pharmaceuticals, Inc. | — | $36M |
| 2300 | Retrotope, Inc. | — | $32M |
| 2301 | Basking Biosciences | — | $29M |
| 2302 | GALATEA BIO INC | — | $3.7M |
| 2303 | Relay Therapeutics | — | $30M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Ernst-Guenter AftingDirector
- Timur ArtemevDirector
- Charles CantorDirector · Executive Officer
- George GaribaldiDirector
- Robert JohnstonDirector
- Yvonne KaoExecutive Officer
- Anil KumarDirector · Executive Officer
- Corey McCannDirector
- Nitin MehtaDirector
- Peter MilnerDirector
- Robert MolinariDirector · Executive Officer
- Harry SaalDirector
- Mikhail ShchepinovDirector · Executive Officer
- Leonardus H.T. Van der PloegDirector
Patents
- Methods For Inhibiting The Progression Of Neurodegenerative Diseasesgranted
- Alleviating Oxidative Stress Disorders With Pufa Derivativesgranted
- Methods Of Treating Amyotrophic Lateral Sclerosisgranted
- Alleviating Oxidative Stress Disorders With Pufa Derivativesgranted
- Site-specific Isotopic Labeling Of 1,4-DIENE Systemsgranted
- Site-specific Isotopic Labeling Of 1,4-DIENE Systemsgranted
- Methods Of Treating Amyotrophic Lateral Sclerosisgranted
- Oxidative Retinal Diseasesgranted
- Neurodegenerative Disorders And Muscle Diseases Implicating Pufasgranted
- Isotopically Modified Components And Therapeutic Uses Thereofgranted
- Site-specific Isotopic Labeling Of 1,4-DIENE Systemsapplication
- Stabilized Polyunsaturated Compounds And Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.